VIVS · VivoSim Labs Inc
Price
Snapshot
50 fields · last close| Market Cap | $4.31M |
| P/E | — |
| Float | 11.74M |
| Beta | 1.59 |
| Volatility | 39.8% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Micro cap |
| Macro sensitivity | High |
| Clavix score | 37 |
| Price | 0.25 |
| Change | +9.82% |
| Prev Close | 0.23 |
| Open | 0.26 |
| Day Low | 0.22 |
| Day High | 0.26 |
| Avg Vol | 1 |
| Avg $ Vol | $282.3K |
| 52W High | 4.20 |
| 52W Low | 0.22 |
| 52W Pos | 0.8% |
| From High | −94.06% |
| From Low | +15.04% |
| Max DD 1Y | −94.53% |
| Spread | 0.10% |
| Liquidity | Thin |
| SMA 20 | −10.76% |
| SMA 50 | −34.40% |
| SMA 200 | −81.60% |
| RSI (14) | 26.8 |
| Vol 30D | 144.2% |
| Vol 90D | 120.1% |
| 1Y Range | 0–4 |
| Daily bars | 353 |
| Perf Week | −19.82% |
| Perf Month | −18.14% |
| Perf Quarter | −79.36% |
| Perf Half Y | −87.25% |
| Perf Year | −93.76% |
| Perf YTD | −86.74% |
| Prev Day | +9.82% |
| Clavix | D- |
| Debt / Eq | 0.00 |
| Curr Ratio | 2.38 |
| Int Cover | -257.0× |
| FCF Margin | — |
| Rev Growth | −51.4% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 32 / 35 |
Clavix risk grade
regraded every trading dayVIVS grades D-, 37 of 100. Steadiest on Sector Resilience (76), most exposed on Price Stability (3, weak). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 32 of 35 in Biotechnology by Clavix score.
How rough the ride is
| VIVS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.59 | 0.51 |
| Volatilityannualized | 39.8% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −94.5% | — |
| Typical daily movemedian absolute daily change | 2.73% | — |
| Days beyond ±3%of the last 252 sessions | 12349% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| VIVS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.59 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| VIVS | |
|---|---|
| 1 week | −19.8% |
| 1 month | −18.1% |
| Year to date | −86.7% |
| 1 year | −93.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| VIVS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 23since 12 Feb |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 6 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| VIVS | |
|---|---|
| Revenue growthyear over year | −51.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openVivoSim Labs presented new data from its NAMkind drug toxicity platform at the EUROTOX 2026 conference in Vienna, showing improved prediction of liver and gastrointestinal safety for both small-molecule drugs and antibody-drug conjugates (ADCs). The presentation covered long-term repeat-dose modeling, gut-barrier testing, and separating the toxic effects of an ADC's payload from its linker chemistry.
VivoSim Labs announced plans to develop a rat liver model that will add to its existing NAMkind human liver platform, with the goal of helping drug companies tell apart liver toxicity that only shows up in rats from risks that also apply to humans.
VivoSim Labs is adding a rat liver model to its NAMkind platform, giving pharmaceutical companies a cross-species testing tool to tell apart liver toxicity unique to rats from toxicity risks that could also affect humans.
VivoSim Labs, Inc. (VIVS) disclosed that Nasdaq notified it on August 17, 2026 that its common stock had not maintained the required minimum closing bid price of $1 per share for 30 consecutive business days. The company has until February 16, 2027 to regain compliance by closing at or above $1 for at least 10 consecutive business days during that period.
VivoSim Labs (Nasdaq: VIVS) announced it regained compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity of $2.5M, following the receipt of a $5.0 million milestone payment from Eli Lilly and $1.0 million released from escrow on July 22, 2026, both tied to the prior sale of its FXR program to Eli Lilly.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ERNA | Ernexa Therapeutics Inc | F | $6.25M | — | 2.69 | Compare |
| QTTB | Q32 Bio Inc | F | $313.8M | 10.52 | 0.51 | Compare |
| CELC | Celcuity Inc | C | $3.94B | — | 0.14 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $4.64B | — | 0.87 | Compare |
| ERAS | Erasca Inc | C | $5.17B | — | 0.71 | Compare |
| PTCT | PTC Therapeutics Inc | B | $5.46B | 7.99 | 0.50 | Compare |
| CGON | CG Oncology Inc | B- | $6.61B | — | 0.21 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.39B | — | 0.41 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.